查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2087739

病毒載體與質體DNA生產市場：2026-2032年全球市場預測（依產品類型、服務類型、工作流程階段、生產平台、生物製程方法、原料、應用、最終用戶和疾病領域分類）

Viral Vector & Plasmid DNA Manufacturing Market by Product Type, Service Type, Workflow Stage, Production Platform, Bioprocess Mode, Source, Application, End User, Disease Area - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，病毒載體和質體DNA 生產市場將成長至 156.7 億美元，複合年成長率為 16.91%。

主要市場統計數據
基準年 2025 52.4億美元
預計年份：2026年 61億美元
預測年份 2032 156.7億美元
複合年成長率 (%) 16.91%

病毒載體和質體DNA的生產既是細胞治療、基因治療、mRNA、疫苗和基因組編輯等研發管線中的關鍵產能瓶頸，也是創造價值的驅動力。除了已通過核准的腺結合病毒、腺病毒和質體類產品外，廣泛的臨床研發管線還需要可擴展的、符合GMP規範的生產、檢驗的分析方法以及穩定的高品質原料供應，這進一步推動了市場需求。

對於合約研發生產機構 (CDMO) 和治療藥物研發公司而言，該產業面臨三大挑戰：縮短研發週期、提高批間一致性以及擴大靈活的生產能力。贊助公司越來越注重評估合作夥伴的端到端能力，包括細胞株開發、上游和下游製程開發、分析測試、放行文件、填充和表面處理工程的整合、低溫運輸規性以及應對監管檢查的準備。

製造業環境的變革性變化

製造環境正從手工式、以宣傳活動為導向的生產模式轉變為以封閉式製程、一次性生物反應器、高通量分析、自動化和標準化品質系統為中心的工業化平台。雖然腺相關病毒（AAV）和慢病毒載體在體內基因治療和體外細胞治療中仍發揮核心作用，但質體DNA作為病毒載體、mRNA模板、基因組編輯工具和DNA疫苗應用的原料，其策略重要性日益凸顯。

人工智慧（AI）的累積影響

人工智慧正整體應用於病毒載體和質體DNA的生產中，以改善製程開發、偏差控制和品管。具體應用包括生物反應器的預測性監測、加速實驗設計、層析法最佳化、異常檢測、批次記錄的自動審查、原料變異性的評估以及功效、純度和安全性資料集的高級分析。

對關鍵區域的洞察

北美憑藉其集中的FDA監管基因療法核准、創業投資支持的生物技術公司、學術轉化研究中心、專業的CDMO基礎設施以及成熟的符合GMP規範的病毒載體和質體DNA生產生態系統，正引領著全球基因療法商業化的步伐。美國仍然是核心市場，這得益於先進療法的批准和積極的臨床試驗活動。同時，加拿大也透過其臨床研究能力、對生物製造的公共投資以及不斷擴大的生技藥品和細胞/基因療法生產人力資源，為全球基因療法商業化做出貢獻。

對關鍵群體的洞察

七國集團（G7）憑藉其主要衛生機構、先進療法研發公司、保險體系、學術研究中心和成熟的GMP基礎設施，在需求、監管和創新方面仍然是最具影響力的集團。北約市場與許多高所得生物製藥經濟體存在重疊，並支撐著有關供應鏈安全、關鍵藥物和生技藥品生產以及先進療法原料（例如病毒載體、質體DNA、一次性系統和特種試劑）供應保障的政策討論。

主要國家的概況

美國是病毒載體和質體DNA生產領域商業性和監管標桿，擁有FDA批准、創業投資、強大的臨床試驗能力、學術創新和專業的CDMO（合約開發和生產）能力。加拿大在臨床研究和生物製造領域的公共投資方面具有優勢，而墨西哥則在更廣泛的生命科學供應鏈和與醫療製造的地理接近性具有優勢。巴西憑藉其製藥基礎、公共衛生基礎設施、疫苗研發經驗以及對先進療法日益成長的需求，代表拉丁美洲的巨大成長機會。

為行業領導者提供的實用建議

產業領導者應優先考慮模組化生產能力、平台化流程和整合分析能力，以縮短前置作業時間並確保首次生產即可達到精準度。投資於高產量生產系統、封閉式製程、可擴展的純化技術、穩健的質體DNA生產、污染控制以及快速的出貨前檢測，對於在病毒載體和質體DNA生產領域實現差異化競爭至關重要。

調查方法

本執行摘要基於二手研究和產業檢驗，利用了公開的監管、科學和技術資訊來源。資訊來源包括FDA和EMA的先進療法指南、公開的批准記錄、臨床試驗註冊資訊、衛生當局出版刊物、同行評審的生產文獻、藥典參考資料以及生物製程行業廣泛認可的說明。

結論

病毒載體和質體DNA的生產已進入高速發展階段，品質、速度、擴充性、數據完整性和監管可靠性決定了競爭優勢。基因治療、細胞療法、mRNA、基因組編輯和下一代疫苗平台等領域的需求不斷成長，但僅靠產能已不足以滿足客戶期望和監管要求。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章：病毒載體與質體DNA生產市場：依產品類型分類

  • 質體DNA
  • 病毒載體
    • 腺結合病毒載體
    • 腺病毒載體
    • 單純皰疹病毒（HSV）載體
    • 慢病毒載體
    • 逆轉錄病毒載體

第8章：病毒載體與質體DNA生產市場：依服務類型分類

  • 分析測試
  • 製造業
  • 製程開發
    • 下游最佳化
    • 配方開發
    • 規模擴大/技術轉移
    • 上游工程最佳化
  • 法規遵從性和CMC支持

第9章：病毒載體與質體DNA生產市場：依工作流程階段分類

  • 下游工藝
    • 捕獲過程
    • 澄清
    • 濃度和緩衝交換
    • 中間純化
    • 最終純化
  • 填充和精加工
  • 船舶檢驗和穩定性測試
  • 上游工程
    • 利用生物反應器進行生產
    • 細胞增殖
    • 轉染/轉導

第10章：病毒載體與質體DNA生產市場：依生產平台分類

  • 細菌
  • 無細胞系統
  • 昆蟲
  • 哺乳動物
  • 東方

第11章：病毒載體與質體DNA生產市場：依生物製程方法分類

  • 批次
  • 文化形式
    • 黏附培養
    • 暫停
  • 聯邦批次
  • 灌注

第12章：病毒載體與質體DNA生產市場：依原料分類

  • 內部生產
  • 外包/CDMO

第13章：病毒載體與質體DNA生產市場：依應用領域分類

  • 細胞療法
  • 基因編輯
  • 基因治療
  • 溶瘤病毒療法
  • 研究與開發
  • 疫苗研發

第14章：病毒載體與質體DNA生產市場：依最終用戶分類

  • 生物製藥公司
  • 合約研發生產組織（CDMO）
  • 受託研究機構（CRO）
  • 研究機構

第15章：病毒載體與質體DNA生產市場：依疾病領域分類

  • 心血管系統
  • 肝病
  • 感染疾病
  • 代謝/內分泌
  • 肌肉骨骼系統
  • 神經病學
  • 腫瘤學
  • 眼科
  • 罕見遺傳疾病

第16章：病毒載體與質體DNA生產市場：依地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第17章：病毒載體與質體DNA生產市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第18章：病毒載體與質體DNA生產市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第19章 競爭情勢

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第20章：公司簡介

  • Advanced BioScience Laboratories, Inc.
  • Akron Biotech
  • Aldevron, LLC
  • Avid Bioservices, Inc.
  • Batavia Biosciences BV
  • BioNTech IMFS GmbH
  • BioSpace, Inc.
  • Biovian Oy
  • c-LEcta GmbH
  • Catalent, Inc.
  • Charles River Laboratories International, Inc.
  • Creative Biogene
  • Cytiva by Danaher Corporation
  • FILTROX AG
  • Forge Biologics By Ajinomoto Co., Inc.
  • FUJIFILM Diosynth Biotechnologies Inc.
  • GE HealthCare Technologies, Inc.
  • Genentech, Inc.
  • GeneOne Life Science, Inc.
  • Genezen Laboratories, Inc.
  • GenScript Biotech Corporation
  • Hillgene Biopharma Co., Ltd.
  • Kaneka Eurogentec SA
  • Lonza Group Ltd.
  • Merck KGaA
  • Miltenyi Biotec BV & Co. KG
  • Oxford Biomedica plc
  • POLYPLUS TRANSFECTION SA
  • REGENXBIO Inc.
  • Revvity, Inc.
  • Takara Bio Inc.
  • Thermo Fisher Scientific Inc.
  • Twist Bioscience Corporation
  • uniQure NV
  • Wuxi AppTec Co., Ltd.
Product Code: MRR-030298DFFC33

The Viral Vector & Plasmid DNA Manufacturing Market is projected to grow by USD 15.67 billion at a CAGR of 16.91% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 5.24 billion
Estimated Year [2026] USD 6.10 billion
Forecast Year [2032] USD 15.67 billion
CAGR (%) 16.91%

Viral vector and plasmid DNA manufacturing has become a critical capacity bottleneck and value driver for cell therapy, gene therapy, mRNA, vaccine, and genome-editing pipelines. Demand is anchored by approved adeno-associated virus (AAV), lentiviral, adenoviral, and plasmid-enabled products, as well as a broad clinical pipeline that requires scalable, GMP-compliant production, validated analytics, and reliable supply of high-quality starting materials.

For contract development and manufacturing organizations (CDMOs) and therapy developers, the industry is defined by three imperatives: shortening development timelines, increasing batch consistency, and expanding flexible capacity. Sponsors increasingly evaluate partners on end-to-end capabilities spanning cell line development, upstream and downstream process development, analytical testing, release documentation, fill-finish integration, cold-chain readiness, and regulatory inspection preparedness.

Transformative Shifts in the Manufacturing Landscape

The landscape is shifting from artisanal, campaign-based production toward industrialized platforms built around closed processing, single-use bioreactors, high-throughput analytics, automation, and standardized quality systems. AAV and lentiviral vectors remain central to in vivo gene therapy and ex vivo cell therapy, while plasmid DNA is gaining strategic importance as a starting material for viral vectors, mRNA templates, genome-editing tools, and DNA vaccine applications.

Capacity strategy is also changing. Large biopharma organizations are balancing internal manufacturing investments with CDMO partnerships to reduce supply risk, while emerging biotechnology firms rely on external partners for speed, technical depth, and regulatory know-how. The most competitive manufacturers are moving from capacity selling to platform selling, offering validated workflows that reduce comparability risk, strengthen process transfer outcomes, and support lifecycle management from early clinical supply to commercial manufacturing.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is increasingly used to improve process development, deviation management, and quality control across viral vector and plasmid DNA manufacturing. Practical applications include predictive bioreactor monitoring, design-of-experiments acceleration, chromatography optimization, anomaly detection, automated batch record review, raw material variability assessment, and advanced analysis of potency, purity, and safety datasets.

The cumulative impact is not a replacement for GMP expertise but a measurable improvement in decision speed, process understanding, and manufacturing robustness. AI-enabled digital twins and advanced analytics help teams anticipate yield variability, identify critical process parameters, and reduce failed runs. Industry leaders are prioritizing validated, explainable AI systems that can withstand regulatory scrutiny and support data integrity expectations under FDA, EMA, ICH, and PIC/S quality frameworks.

Key Regional Insights

North America leads global commercialization momentum due to the concentration of FDA-regulated gene therapy approvals, venture-backed biotechnology companies, academic translational centers, specialized CDMO infrastructure, and a mature ecosystem for GMP viral vector and plasmid DNA manufacturing. The United States remains the anchor market, supported by advanced therapy approvals and deep clinical trial activity, while Canada contributes clinical research capacity, public biomanufacturing investment, and a growing talent base for biologics and cell and gene therapy production.

Europe is characterized by strong regulatory maturity, advanced cell and gene therapy clusters, and public-private manufacturing initiatives across the European Union and the United Kingdom. The region benefits from established advanced therapy medicinal product frameworks, hospital-linked treatment networks, and cross-border scientific collaboration. Asia-Pacific is expanding rapidly as China, Japan, South Korea, India, Singapore, and Australia invest in clinical development, bioprocessing talent, domestic manufacturing resilience, plasmid DNA supply, and technology transfer capabilities.

Latin America is earlier in adoption but shows rising interest in advanced therapies through Brazil and Mexico, where public health systems, pharmaceutical manufacturing bases, and clinical research infrastructure are shaping long-term opportunity. The Middle East is building life sciences hubs through healthcare diversification strategies, particularly in GCC countries that are prioritizing specialty care, biologics infrastructure, and strategic manufacturing partnerships. Africa remains nascent, with opportunities tied to vaccine manufacturing, technology transfer, workforce training, regulatory strengthening, and regional biomanufacturing capacity building.

Key Group Insights

The G7 remains the most influential demand, regulatory, and innovation bloc because it includes major health authorities, advanced therapy developers, payer systems, academic research centers, and mature GMP infrastructure. NATO markets overlap with many high-income biopharma economies, supporting policy discussions around supply chain security, critical medicines, biologics manufacturing, and resilience for advanced therapy inputs such as viral vectors, plasmid DNA, single-use systems, and specialty reagents.

The European Union plays a central role through harmonized regulatory pathways, cross-border clinical trial coordination, and funding mechanisms that support advanced therapy medicinal products and biomanufacturing modernization. BRICS countries are increasingly relevant as China, India, and Brazil expand biologics capacity, clinical research activity, vaccine platforms, and local manufacturing ambitions, while Russia's participation is affected by geopolitical constraints and supply chain limitations.

ASEAN is emerging as a regional manufacturing and clinical operations corridor, with Singapore acting as a high-value bioprocessing hub and neighboring countries strengthening healthcare access, clinical infrastructure, and investment promotion for life sciences. The GCC is positioning life sciences as part of economic diversification, with opportunities in fill-finish, technology transfer, specialty hospital networks, regulatory capability building, and partnerships that can support future viral vector and plasmid DNA manufacturing readiness.

Key Country Insights

The United States is the leading commercial and regulatory reference point for viral vector and plasmid DNA manufacturing, supported by FDA approvals, venture capital, clinical trial depth, academic innovation, and specialized CDMO capacity. Canada adds clinical research strength and public biomanufacturing investments, while Mexico offers proximity advantages for broader life sciences supply chains and medical manufacturing. Brazil is the leading Latin American opportunity due to its pharmaceutical base, public health infrastructure, vaccine experience, and growing interest in advanced therapy access.

In Europe, the United Kingdom, Germany, France, Italy, and Spain support advanced therapy research, GMP manufacturing, translational medicine, and hospital-based treatment networks. The United Kingdom benefits from strong cell and gene therapy clinical infrastructure, Germany from engineering depth and bioprocessing expertise, France from national biomanufacturing initiatives, Italy from academic and hospital-linked advanced therapy activity, and Spain from clinical trial participation and biomedical research networks. Russia has scientific capabilities but faces geopolitical, regulatory, financing, and supply chain constraints that limit integration with global advanced therapy manufacturing networks.

China is scaling aggressively across gene therapy, plasmid DNA, viral vector development, and CDMO services, supported by expanding clinical activity and domestic innovation policies. India is strengthening biologics, vaccines, plasmid production, and cost-efficient process development capabilities, while Japan maintains a favorable regenerative medicine framework and strong regulatory experience with advanced therapies. South Korea is investing in biomanufacturing scale, quality systems, and technology-driven life sciences infrastructure, and Australia remains important for early-phase clinical trials, translational research, and Asia-Pacific advanced therapy collaboration.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize modular capacity, platform processes, and integrated analytical capabilities to reduce lead times and improve right-first-time manufacturing. Investments in high-yield producer systems, closed processing, scalable purification, robust plasmid DNA production, contamination control, and rapid release testing are essential for competitive differentiation in viral vector and plasmid DNA manufacturing.

CDMOs and therapy developers should build supplier redundancy for critical raw materials, strengthen plasmid DNA sourcing strategies, and maintain transparent technology transfer playbooks. Executive teams should also invest in regulatory intelligence, workforce development, digital batch records, data integrity controls, and validated AI analytics to improve compliance, reduce deviations, support comparability packages, and increase sponsor confidence across clinical and commercial programs.

Research Methodology

This executive summary is based on secondary research and industry triangulation using publicly available regulatory, scientific, and technical sources. Inputs include FDA and EMA advanced therapy guidance, public approval records, clinical trial registries, health authority publications, peer-reviewed manufacturing literature, pharmacopeial references, and recognized bioprocessing industry commentary.

The assessment emphasizes verified trends rather than speculative forecasts. Regional, group, and country insights were evaluated through observable indicators such as regulatory maturity, clinical development activity, CDMO presence, biomanufacturing investment, public policy initiatives, workforce availability, quality system readiness, and supply chain preparedness for viral vectors and plasmid DNA.

Conclusion

Viral vector and plasmid DNA manufacturing is entering an execution-focused phase in which quality, speed, scalability, data integrity, and regulatory reliability determine competitive positioning. Demand is expanding across gene therapy, cell therapy, mRNA, genome editing, and next-generation vaccine platforms, but capacity alone is no longer sufficient to meet sponsor expectations or regulatory requirements.

The strongest manufacturers will combine flexible infrastructure, proven platform technologies, advanced analytics, resilient raw material strategies, and global regulatory competence. Organizations that industrialize processes while preserving scientific adaptability will be best positioned to support the evolving advanced therapy manufacturing ecosystem.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Viral Vector & Plasmid DNA Manufacturing Market, by Product Type

  • 7.1. Plasmid DNA
  • 7.2. Viral Vector
    • 7.2.1. Adeno-Associated Viral Vectors
    • 7.2.2. Adenoviral Vectors
    • 7.2.3. Herpes Simplex Virus (HSV) Vectors
    • 7.2.4. Lentiviral Vectors
    • 7.2.5. Retroviral Vectors

8. Viral Vector & Plasmid DNA Manufacturing Market, by Service Type

  • 8.1. Analytical Testing
  • 8.2. Manufacturing
  • 8.3. Process Development
    • 8.3.1. Downstream Optimization
    • 8.3.2. Formulation Development
    • 8.3.3. Scale-Up/Technology Transfer
    • 8.3.4. Upstream Optimization
  • 8.4. Regulatory & CMC Support

9. Viral Vector & Plasmid DNA Manufacturing Market, by Workflow Stage

  • 9.1. Downstream Processing
    • 9.1.1. Capture
    • 9.1.2. Clarification
    • 9.1.3. Concentration/Buffer Exchange
    • 9.1.4. Intermediate Purification
    • 9.1.5. Polishing
  • 9.2. Fill & Finish
  • 9.3. Release & Stability Testing
  • 9.4. Upstream Processing
    • 9.4.1. Bioreactor Production
    • 9.4.2. Cell Expansion
    • 9.4.3. Transfection/Transduction

10. Viral Vector & Plasmid DNA Manufacturing Market, by Production Platform

  • 10.1. Bacterial
  • 10.2. Cell-Free Systems
  • 10.3. Insect
  • 10.4. Mammalian
  • 10.5. Yeast

11. Viral Vector & Plasmid DNA Manufacturing Market, by Bioprocess Mode

  • 11.1. Batch
  • 11.2. Culture Format
    • 11.2.1. Adherent
    • 11.2.2. Suspension
  • 11.3. Fed-Batch
  • 11.4. Perfusion

12. Viral Vector & Plasmid DNA Manufacturing Market, by Source

  • 12.1. In-House Manufacturing
  • 12.2. Outsourced/CDMO

13. Viral Vector & Plasmid DNA Manufacturing Market, by Application

  • 13.1. Cell Therapy
  • 13.2. Gene Editing
  • 13.3. Gene Therapy
  • 13.4. Oncolytic Virotherapy
  • 13.5. Research & Developement
  • 13.6. Vaccine Development

14. Viral Vector & Plasmid DNA Manufacturing Market, by End User

  • 14.1. Biopharmaceutical Companies
  • 14.2. Contract Development & Manufacturing Organizations (CDMOs)
  • 14.3. Contract Research Organizations (CROs)
  • 14.4. Research Institutions

15. Viral Vector & Plasmid DNA Manufacturing Market, by Disease Area

  • 15.1. Cardiovascular
  • 15.2. Hepatic Diseases
  • 15.3. Infectious Diseases
  • 15.4. Metabolic/Endocrine
  • 15.5. Musculoskeletal
  • 15.6. Neurology
  • 15.7. Oncology
  • 15.8. Ophthalmology
  • 15.9. Rare Genetic Disorders

16. Viral Vector & Plasmid DNA Manufacturing Market, by Region

  • 16.1. Asia-Pacific
  • 16.2. North America
  • 16.3. Latin America
  • 16.4. Europe
  • 16.5. Middle East
  • 16.6. Africa

17. Viral Vector & Plasmid DNA Manufacturing Market, by Group

  • 17.1. ASEAN
  • 17.2. GCC
  • 17.3. European Union
  • 17.4. BRICS
  • 17.5. G7
  • 17.6. NATO

18. Viral Vector & Plasmid DNA Manufacturing Market, by Country

  • 18.1. United States
  • 18.2. Canada
  • 18.3. Mexico
  • 18.4. Brazil
  • 18.5. United Kingdom
  • 18.6. Germany
  • 18.7. France
  • 18.8. Russia
  • 18.9. Italy
  • 18.10. Spain
  • 18.11. China
  • 18.12. India
  • 18.13. Japan
  • 18.14. Australia
  • 18.15. South Korea

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025

20. Company Profiles

  • 20.1. Advanced BioScience Laboratories, Inc.
  • 20.2. Akron Biotech
  • 20.3. Aldevron, LLC
  • 20.4. Avid Bioservices, Inc.
  • 20.5. Batavia Biosciences B.V.
  • 20.6. BioNTech IMFS GmbH
  • 20.7. BioSpace, Inc.
  • 20.8. Biovian Oy
  • 20.9. c-LEcta GmbH
  • 20.10. Catalent, Inc.
  • 20.11. Charles River Laboratories International, Inc.
  • 20.12. Creative Biogene
  • 20.13. Cytiva by Danaher Corporation
  • 20.14. FILTROX AG
  • 20.15. Forge Biologics By Ajinomoto Co., Inc.
  • 20.16. FUJIFILM Diosynth Biotechnologies Inc.
  • 20.17. GE HealthCare Technologies, Inc.
  • 20.18. Genentech, Inc.
  • 20.19. GeneOne Life Science, Inc.
  • 20.20. Genezen Laboratories, Inc.
  • 20.21. GenScript Biotech Corporation
  • 20.22. Hillgene Biopharma Co., Ltd.
  • 20.23. Kaneka Eurogentec S.A.
  • 20.24. Lonza Group Ltd.
  • 20.25. Merck KGaA
  • 20.26. Miltenyi Biotec B.V. & Co. KG
  • 20.27. Oxford Biomedica plc
  • 20.28. POLYPLUS TRANSFECTION S.A.
  • 20.29. REGENXBIO Inc.
  • 20.30. Revvity, Inc.
  • 20.31. Takara Bio Inc.
  • 20.32. Thermo Fisher Scientific Inc.
  • 20.33. Twist Bioscience Corporation
  • 20.34. uniQure N.V.
  • 20.35. Wuxi AppTec Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY WORKFLOW STAGE, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY WORKFLOW STAGE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY PRODUCTION PLATFORM, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY PRODUCTION PLATFORM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY BIOPROCESS MODE, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY BIOPROCESS MODE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY SOURCE, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY SOURCE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY APPLICATION, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY DISEASE AREA, 2025 VS 2032 (%)
  • FIGURE 25. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY DISEASE AREA, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 27. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 29. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 30. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 31. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL PLASMID DNA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL PLASMID DNA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL PLASMID DNA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL VIRAL VECTOR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL VIRAL VECTOR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL VIRAL VECTOR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ADENO-ASSOCIATED VIRAL VECTORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ADENO-ASSOCIATED VIRAL VECTORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ADENO-ASSOCIATED VIRAL VECTORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ADENOVIRAL VECTORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ADENOVIRAL VECTORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ADENOVIRAL VECTORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL HERPES SIMPLEX VIRUS (HSV) VECTORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL HERPES SIMPLEX VIRUS (HSV) VECTORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL HERPES SIMPLEX VIRUS (HSV) VECTORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL LENTIVIRAL VECTORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL LENTIVIRAL VECTORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL LENTIVIRAL VECTORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL RETROVIRAL VECTORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL RETROVIRAL VECTORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL RETROVIRAL VECTORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ANALYTICAL TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ANALYTICAL TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ANALYTICAL TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL MANUFACTURING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL MANUFACTURING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL PROCESS DEVELOPMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL PROCESS DEVELOPMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL PROCESS DEVELOPMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL DOWNSTREAM OPTIMIZATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL DOWNSTREAM OPTIMIZATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL DOWNSTREAM OPTIMIZATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL FORMULATION DEVELOPMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL FORMULATION DEVELOPMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL FORMULATION DEVELOPMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL SCALE-UP/TECHNOLOGY TRANSFER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL SCALE-UP/TECHNOLOGY TRANSFER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL SCALE-UP/TECHNOLOGY TRANSFER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL UPSTREAM OPTIMIZATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL UPSTREAM OPTIMIZATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL UPSTREAM OPTIMIZATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL REGULATORY & CMC SUPPORT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL REGULATORY & CMC SUPPORT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL REGULATORY & CMC SUPPORT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY WORKFLOW STAGE, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL DOWNSTREAM PROCESSING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL DOWNSTREAM PROCESSING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL DOWNSTREAM PROCESSING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL CAPTURE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL CAPTURE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL CAPTURE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL CLARIFICATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL CLARIFICATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL CLARIFICATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL CONCENTRATION/BUFFER EXCHANGE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL CONCENTRATION/BUFFER EXCHANGE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL CONCENTRATION/BUFFER EXCHANGE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL INTERMEDIATE PURIFICATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL INTERMEDIATE PURIFICATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL INTERMEDIATE PURIFICATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL POLISHING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL POLISHING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL POLISHING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL FILL & FINISH MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL FILL & FINISH MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL FILL & FINISH MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL RELEASE & STABILITY TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL RELEASE & STABILITY TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL RELEASE & STABILITY TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL UPSTREAM PROCESSING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL UPSTREAM PROCESSING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL UPSTREAM PROCESSING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL BIOREACTOR PRODUCTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL BIOREACTOR PRODUCTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL BIOREACTOR PRODUCTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL CELL EXPANSION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL CELL EXPANSION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL CELL EXPANSION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL TRANSFECTION/TRANSDUCTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL TRANSFECTION/TRANSDUCTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL TRANSFECTION/TRANSDUCTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY PRODUCTION PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL BACTERIAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL BACTERIAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL BACTERIAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL CELL-FREE SYSTEMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL CELL-FREE SYSTEMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL CELL-FREE SYSTEMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL INSECT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL INSECT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL INSECT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL MAMMALIAN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL MAMMALIAN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL MAMMALIAN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL YEAST MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL YEAST MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL YEAST MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY BIOPROCESS MODE, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL BATCH MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL BATCH MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL BATCH MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL CULTURE FORMAT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL CULTURE FORMAT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL CULTURE FORMAT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL ADHERENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL ADHERENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL ADHERENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL SUSPENSION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL SUSPENSION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL SUSPENSION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL FED-BATCH MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL FED-BATCH MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL FED-BATCH MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL PERFUSION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL PERFUSION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL PERFUSION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL IN-HOUSE MANUFACTURING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL IN-HOUSE MANUFACTURING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL IN-HOUSE MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL OUTSOURCED/CDMO MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL OUTSOURCED/CDMO MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL OUTSOURCED/CDMO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL CELL THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL CELL THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL GENE EDITING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL GENE EDITING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL GENE EDITING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL GENE THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL GENE THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL GENE THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL ONCOLYTIC VIROTHERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL ONCOLYTIC VIROTHERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL ONCOLYTIC VIROTHERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL RESEARCH & DEVELOPEMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL RESEARCH & DEVELOPEMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL RESEARCH & DEVELOPEMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL VACCINE DEVELOPMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL VACCINE DEVELOPMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL VACCINE DEVELOPMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL BIOPHARMACEUTICAL COMPANIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL BIOPHARMACEUTICAL COMPANIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL BIOPHARMACEUTICAL COMPANIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 151. GLOBAL CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATIONS (CDMOS) MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATIONS (CDMOS) MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATIONS (CDMOS) MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 154. GLOBAL CONTRACT RESEARCH ORGANIZATIONS (CROS) MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 155. GLOBAL CONTRACT RESEARCH ORGANIZATIONS (CROS) MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 156. GLOBAL CONTRACT RESEARCH ORGANIZATIONS (CROS) MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 157. GLOBAL RESEARCH INSTITUTIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 158. GLOBAL RESEARCH INSTITUTIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 159. GLOBAL RESEARCH INSTITUTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 160. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY DISEASE AREA, 2018-2032 (USD MILLION)
  • TABLE 161. GLOBAL CARDIOVASCULAR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 162. GLOBAL CARDIOVASCULAR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 163. GLOBAL CARDIOVASCULAR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 164. GLOBAL HEPATIC DISEASES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 165. GLOBAL HEPATIC DISEASES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 166. GLOBAL HEPATIC DISEASES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 167. GLOBAL INFECTIOUS DISEASES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 168. GLOBAL INFECTIOUS DISEASES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 169. GLOBAL INFECTIOUS DISEASES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 170. GLOBAL METABOLIC/ENDOCRINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 171. GLOBAL METABOLIC/ENDOCRINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 172. GLOBAL METABOLIC/ENDOCRINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 173. GLOBAL MUSCULOSKELETAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 174. GLOBAL MUSCULOSKELETAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 175. GLOBAL MUSCULOSKELETAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 176. GLOBAL NEUROLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 177. GLOBAL NEUROLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 178. GLOBAL NEUROLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 179. GLOBAL ONCOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 180. GLOBAL ONCOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 181. GLOBAL ONCOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 182. GLOBAL OPHTHALMOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 183. GLOBAL OPHTHALMOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 184. GLOBAL OPHTHALMOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 185. GLOBAL RARE GENETIC DISORDERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 186. GLOBAL RARE GENETIC DISORDERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 187. GLOBAL RARE GENETIC DISORDERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 188. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 189. ASIA-PACIFIC VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 190. ASIA-PACIFIC VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. ASIA-PACIFIC VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 192. ASIA-PACIFIC VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 193. ASIA-PACIFIC VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 194. ASIA-PACIFIC VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY WORKFLOW STAGE, 2018-2032 (USD MILLION)
  • TABLE 195. ASIA-PACIFIC VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2032 (USD MILLION)
  • TABLE 196. ASIA-PACIFIC VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2032 (USD MILLION)
  • TABLE 197. ASIA-PACIFIC VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY PRODUCTION PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 198. ASIA-PACIFIC VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY BIOPROCESS MODE, 2018-2032 (USD MILLION)
  • TABLE 199. ASIA-PACIFIC VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY CULTURE FORMAT, 2018-2032 (USD MILLION)
  • TABLE 200. ASIA-PACIFIC VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 201. ASIA-PACIFIC VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 202. ASIA-PACIFIC VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 203. ASIA-PACIFIC VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY DISEASE AREA, 2018-2032 (USD MILLION)
  • TABLE 204. NORTH AMERICA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 205. NORTH AMERICA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 206. NORTH AMERICA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 207. NORTH AMERICA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 208. NORTH AMERICA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 209. NORTH AMERICA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY WORKFLOW STAGE, 2018-2032 (USD MILLION)
  • TABLE 210. NORTH AMERICA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2032 (USD MILLION)
  • TABLE 211. NORTH AMERICA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2032 (USD MILLION)
  • TABLE 212. NORTH AMERICA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY PRODUCTION PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 213. NORTH AMERICA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY BIOPROCESS MODE, 2018-2032 (USD MILLION)
  • TABLE 214. NORTH AMERICA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY CULTURE FORMAT, 2018-2032 (USD MILLION)
  • TABLE 215. NORTH AMERICA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 216. NORTH AMERICA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 217. NORTH AMERICA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 218. NORTH AMERICA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY DISEASE AREA, 2018-2032 (USD MILLION)
  • TABLE 219. LATIN AMERICA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 220. LATIN AMERICA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 221. LATIN AMERICA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 222. LATIN AMERICA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 223. LATIN AMERICA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 224. LATIN AMERICA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY WORKFLOW STAGE, 2018-2032 (USD MILLION)
  • TABLE 225. LATIN AMERICA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2032 (USD MILLION)
  • TABLE 226. LATIN AMERICA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2032 (USD MILLION)
  • TABLE 227. LATIN AMERICA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY PRODUCTION PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 228. LATIN AMERICA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY BIOPROCESS MODE, 2018-2032 (USD MILLION)
  • TABLE 229. LATIN AMERICA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY CULTURE FORMAT, 2018-2032 (USD MILLION)
  • TABLE 230. LATIN AMERICA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 231. LATIN AMERICA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 232. LATIN AMERICA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 233. LATIN AMERICA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY DISEASE AREA, 2018-2032 (USD MILLION)
  • TABLE 234. EUROPE VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 235. EUROPE VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 236. EUROPE VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 237. EUROPE VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 238. EUROPE VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 239. EUROPE VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY WORKFLOW STAGE, 2018-2032 (USD MILLION)
  • TABLE 240. EUROPE VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2032 (USD MILLION)
  • TABLE 241. EUROPE VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2032 (USD MILLION)
  • TABLE 242. EUROPE VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY PRODUCTION PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 243. EUROPE VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY BIOPROCESS MODE, 2018-2032 (USD MILLION)
  • TABLE 244. EUROPE VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY CULTURE FORMAT, 2018-2032 (USD MILLION)
  • TABLE 245. EUROPE VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 246. EUROPE VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 247. EUROPE VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 248. EUROPE VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY DISEASE AREA, 2018-2032 (USD MILLION)
  • TABLE 249. MIDDLE EAST VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 250. MIDDLE EAST VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 251. MIDDLE EAST VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 252. MIDDLE EAST VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 253. MIDDLE EAST VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 254. MIDDLE EAST VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY WORKFLOW STAGE, 2018-2032 (USD MILLION)
  • TABLE 255. MIDDLE EAST VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2032 (USD MILLION)
  • TABLE 256. MIDDLE EAST VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2032 (USD MILLION)
  • TABLE 257. MIDDLE EAST VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY PRODUCTION PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 258. MIDDLE EAST VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY BIOPROCESS MODE, 2018-2032 (USD MILLION)
  • TABLE 259. MIDDLE EAST VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY CULTURE FORMAT, 2018-2032 (USD MILLION)
  • TABLE 260. MIDDLE EAST VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 261. MIDDLE EAST VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 262. MIDDLE EAST VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 263. MIDDLE EAST VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY DISEASE AREA, 2018-2032 (USD MILLION)
  • TABLE 264. AFRICA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 265. AFRICA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 266. AFRICA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 267. AFRICA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 268. AFRICA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 269. AFRICA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY WORKFLOW STAGE, 2018-2032 (USD MILLION)
  • TABLE 270. AFRICA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2032 (USD MILLION)
  • TABLE 271. AFRICA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2032 (USD MILLION)
  • TABLE 272. AFRICA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY PRODUCTION PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 273. AFRICA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY BIOPROCESS MODE, 2018-2032 (USD MILLION)
  • TABLE 274. AFRICA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY CULTURE FORMAT, 2018-2032 (USD MILLION)
  • TABLE 275. AFRICA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 276. AFRICA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 277. AFRICA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 278. AFRICA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY DISEASE AREA, 2018-2032 (USD MILLION)
  • TABLE 279. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 280. ASEAN VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 281. ASEAN VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 282. ASEAN VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 283. ASEAN VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 284. ASEAN VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 285. ASEAN VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY WORKFLOW STAGE, 2018-2032 (USD MILLION)
  • TABLE 286. ASEAN VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2032 (USD MILLION)
  • TABLE 287. ASEAN VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2032 (USD MILLION)
  • TABLE 288. ASEAN VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY PRODUCTION PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 289. ASEAN VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY BIOPROCESS MODE, 2018-2032 (USD MILLION)
  • TABLE 290. ASEAN VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY CULTURE FORMAT, 2018-2032 (USD MILLION)
  • TABLE 291. ASEAN VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 292. ASEAN VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 293. ASEAN VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 294. ASEAN VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY DISEASE AREA, 2018-2032 (USD MILLION)
  • TABLE 295. GCC VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 296. GCC VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 297. GCC VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 298. GCC VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 299. GCC VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 300. GCC VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY WORKFLOW STAGE, 2018-2032 (USD MILLION)
  • TABLE 301. GCC VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2032 (USD MILLION)
  • TABLE 302. GCC VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2032 (USD MILLION)
  • TABLE 303. GCC VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY PRODUCTION PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 304. GCC VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY BIOPROCESS MODE, 2018-2032 (USD MILLION)
  • TABLE 305. GCC VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY CULTURE FORMAT, 2018-2032 (USD MILLION)
  • TABLE 306. GCC VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 307. GCC VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 308. GCC VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 309. GCC VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY DISEASE AREA, 2018-2032 (USD MILLION)
  • TABLE 310. EUROPEAN UNION VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 311. EUROPEAN UNION VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 312. EUROPEAN UNION VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 313. EUROPEAN UNION VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 314. EUROPEAN UNION VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 315. EUROPEAN UNION VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY WORKFLOW STAGE, 2018-2032 (USD MILLION)
  • TABLE 316. EUROPEAN UNION VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2032 (USD MILLION)
  • TABLE 317. EUROPEAN UNION VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2032 (USD MILLION)
  • TABLE 318. EUROPEAN UNION VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY PRODUCTION PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 319. EUROPEAN UNION VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY BIOPROCESS MODE, 2018-2032 (USD MILLION)
  • TABLE 320. EUROPEAN UNION VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY CULTURE FORMAT, 2018-2032 (USD MILLION)
  • TABLE 321. EUROPEAN UNION VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 322. EUROPEAN UNION VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 323. EUROPEAN UNION VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 324. EUROPEAN UNION VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY DISEASE AREA, 2018-2032 (USD MILLION)
  • TABLE 325. BRICS VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 326. BRICS VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 327. BRICS VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 328. BRICS VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 329. BRICS VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 330. BRICS VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY WORKFLOW STAGE, 2018-2032 (USD MILLION)
  • TABLE 331. BRICS VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-203